4 Results for "

self-grooming

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "self-grooming" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-18678A
CAS No.: 1607799-13-2
Synonyms: PT-141 Acetate
Target:  

Melanocortin Receptor

Research Areas:  

Metabolic Disease

Bremelanotide (PT-141) Acetate is a melanocortin receptor agonist. Bremelanotide Acetate can activate MC4R and increases dopamine release. Bremelanotide Acetate induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide Acetate can be used for the research of hypoactive sexual desire disorders .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18678
CAS No.: 189691-06-3
Synonyms: PT-141
Bremelanotide (PT-141) is a melanocortin receptor agonist. Bremelanotide can activate MC4R and increases dopamine release. Bremelanotide induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide can be used for the research of hypoactive sexual desire disorders .
loading...
    loading...
Cat. No.: HY-163345
CAS No.: 1448808-50-1
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

5-HT7R antagonist 2 (compound 4h) is a 5-HT7R antagonist that antagonizes the G protein and β-arrestin signaling pathways, with a Ki of 67 nM, the IC50 values in cAMP and Tango tests were 2.59 μM and 39.57 μM, respectively. 5-HT7R antagonist 2 has an effect on neurogenesis and can reduce repetitive behaviors related to autism spectrum disorder (ASD) and restore neurogenesis of ASD impairment .
loading...
    loading...
Cat. No.: HY-15080
CAS No.: 143691-37-6
Synonyms: LY 293606
Target:  

iGluR

GYKI 53405 (LY 293606) is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .
loading...
    loading...